Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Amgen's Blincyto Adds Pediatric Claim For Leukemia
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Neurocrine Gets First Drug For Tardive Dyskinesia To FDA
Teva CRL Response For Huntington’s Drug Targeted For September
Pediatric Study Requirements For Cancer Have FDA Support, But Pose Industry Challenges
Keeping Track: FDA Approves Epclusa, Designates Four Breakthrough Therapies, Files Burst Of Applications
Keeping Track: Mitsubishi ALS NDA; Opko’s Rayaldee Approval; Avycaz Label Extension
Ariad Narrows Geographic Reach To Maximize Commercial Resources
Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road
Keeping Track: Tecentriq, Opdivo Approvals Intensify Spotlight On Immuno-Oncology


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts